VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer

Dalaveris, Eleftherios; Kerenidi, Theodora; Katsabeki-Katsafli, Alexandra; Kiropoulos, Theodoros; Tanou, Kalliopi; Gourgoulianis, Konstantinos; Κostikas, Κonstantinos

doi:10.1016/j.lungcan.2008.08.015

Cited by 90 publications

(76 citation statements)

References 30 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with lung cancer had greater levels of EBC TNF-α, independent of whether they were yet to commence treatment, undergoing treatment at the time of collection or had completed their treatment, when compared with healthy controls. This finding is consistent with a previous study that reported statistically elevated levels of TNF-α in the EBC of patients with lung cancer prior to treatment when compared with controls [16].…”

Section: Discussionsupporting

confidence: 93%

“…TNF-α is highly expressed in tumours and is elevated in the serum of patients with non-small cell lung cancer (NSCLC) when compared with control subjects [15,16]. TNF-α is elevated in the EBC of patients with lung cancer when compared with control subjects [16]. TNF-α is also a mediator for initiating cellular apoptosis but its apoptotic pathways may be circumvented by certain tumour cell characteristics [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tumour Necrosis Factor Alpha and Oxidative Stress in the Breath Condensate of Those with Non-Small Cell Lung Cancer

Chan¹,

Sivagnanam²,

Zhang³

et al. 2012

JCT

View full text Add to dashboard Cite

Background and Aims: Lung cancer is a leading cause of cancer mortality worldwide and is associated with the release of tumour necrosis factor-α (TNF-α), subsequent cellular apoptosis and the generation of oxidative stress. Exhaled breath condensate (EBC) analysis is a non-invasive method for sampling biofluids from the lower respiratory tract. This study aimed to evaluate possible biomarkers of lung cancer by measuring the levels of TNF-α and the oxidation of ascorbic acid in EBC. Patients with lung cancer were enrolled into the study prior to treatment, during treatment and post-treatment, and results compared with an age-matched control population. Material and Methods: Patients with Stages II-IV non small cell lung cancer (NSCLC) were recruited prior to and at stages of their treatment. EBC levels of TNF-α, and rate of ascorbic acid oxidation were measured. Results: A total of 19 patients with NSCLC (mean age 71.37 ± 7.77 yr) and 25 age-matched control subjects were enrolled. Levels of EBC TNF-α were elevated in the EBC of patients with lung cancer compared with control subjects (1.02 ± 0.07 pg/ml vs 0.51 ± 0.06 pg/ml, p < 0.0001). Moreover, the rate of ascorbic acid oxidation was significantly greater in the EBC of patients with lung cancer compared with control subjects (2.20% [0.4 -11.0] vs 1.00% [0.1 -8.5], p = 0.0244). Conclusion: TNF-α and the rate of ascorbic acid oxidation was elevated in the EBC of patients with lung cancer regardless of treatment. Longitudinal studies in a larger population are required to evaluate these markers for the effect of treatment and prognosis.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Tumour Necrosis Factor Alpha and Oxidative Stress in the Breath Condensate of Those with Non-Small Cell Lung Cancer

Chan¹,

Sivagnanam²,

Zhang³

et al. 2012

JCT

View full text Add to dashboard Cite

show abstract

“…TNF-α generated in a tumor microenvironment can function as an endogenous tumor promoter, and also as an inducer of the genes involved in inflammation and cell survival. It has been demonstrated that inflammatory cytokines were upregulated in specimens of human lung cancer [30,31]. In this study, we confirmed TNF-α induced COX-2 expression in A549 cells, suggesting abundant COX-2 expression in cancer environments.…”

Section: Discussionsupporting

confidence: 82%

Redox Factor-1 Inhibits Cyclooxygenase-2 Expression via Inhibiting of p38 MAPK in the A549 Cells

Yoo

Kim

Lee

et al. 2010

Korean J Physiol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Although several other researchers have reported increased oxidative stress in patients with lung cancer prior to chemotherapy (Zieba et al, 2001;Dalaveris et al, 2009;de Castro et al, 2006), we did not observe increase levels at the beginning of chemotherapy compared with levels previously reported for healthy subjects, although this comparison must be considered carefully due to differences in measurement method as previously discussed.…”

Section: Discussioncontrasting

confidence: 77%

Assessment of 8-isoprostane (8-isoPGF₂_α) in Urine of Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Chemotherapy

Johns

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Abstract8-isoprostane (8-isoPGF 2α ) is a reliable marker and considered a gold standard for lipid peroxidation. There are very few reports of 8-isoprostane levels in cancer patients, and in patients undergoing chemotherapy. Oxidative stress is however expected and has been observed in patients with cancer. This study measured 8-isoprostane levels in urine by ELISA of 25 patients undergoing chemotherapy for advanced non-small cell lung cancer, at cycles 1, 2, and 3 of treatment. It considers the creatinine clearance of the patients, and correction of 8-isoprostane levels by creatinine clearance, and overnight urine volume methods. The average 8-isoprostane levels in urine increased more than 6 to 12 fold on chemotherapy treatment, from 532 ±587 pg/mL at cycle 1, 6181 ± 4334 at cycle 2, and 5511 ± 2055 at cycle 3. Similar results were obtained if 8-isoprostane levels were corrected for overnight urine volume, giving averages of 285 ± 244 µg at cycle 1, 4122 ± 3349 at cycle 2, and 3266 ± 1200 at cycle 3. No significant difference was seen in average total overnight urine volume or number of urinations between chemotherapy cycles except for a large variation in urine volume between cycle 2 and 3. Creatinine levels were significantly different only between cycles 1 and 2 (p=0.016). In conclusion, cisplatin therapy has been shown to induce high levels of lipid peroxidation in lung cancer patients and can be assessed from the 8-isoprostane marker in overnight urine, with or without urine volume correction.

show abstract

VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer

Cited by 90 publications

References 30 publications

Tumour Necrosis Factor Alpha and Oxidative Stress in the Breath Condensate of Those with Non-Small Cell Lung Cancer

Tumour Necrosis Factor Alpha and Oxidative Stress in the Breath Condensate of Those with Non-Small Cell Lung Cancer

Redox Factor-1 Inhibits Cyclooxygenase-2 Expression via Inhibiting of p38 MAPK in the A549 Cells

Assessment of 8-isoprostane (8-isoPGF₂_α) in Urine of Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Chemotherapy

Contact Info

Product

Resources

About

VEGF, TNF-α and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer

Cited by 90 publications

References 30 publications

Tumour Necrosis Factor Alpha and Oxidative Stress in the Breath Condensate of Those with Non-Small Cell Lung Cancer

Tumour Necrosis Factor Alpha and Oxidative Stress in the Breath Condensate of Those with Non-Small Cell Lung Cancer

Redox Factor-1 Inhibits Cyclooxygenase-2 Expression via Inhibiting of p38 MAPK in the A549 Cells

Assessment of 8-isoprostane (8-isoPGF2α) in Urine of Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Chemotherapy

Contact Info

Product

Resources

About

Assessment of 8-isoprostane (8-isoPGF₂_α) in Urine of Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Chemotherapy